Storia in 8 fonti

Melanoma Vaccine Halves Risk of Recurrence, Metastasis Over 5 Years

Adjuvant approach will need confirmation from ongoing phase III trial, says expert

Raccontata danpr.orgnbcnews.commorningstar.comansa.itindependent.co.ukforbes.comliberoquotidiano.itmedpagetoday.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo3 g fa

Melanoma Vaccine Halves Risk of Recurrence, Metastasis Over 5 Years

Adjuvant approach will need confirmation from ongoing phase III trial, says expert

originale

nbcnews.com4 g fa

A personalized vaccine for melanoma cut the risk of cancer returning after five years

If the vaccine is effective in a late-stage trial, it would be “paradigm-shifting,” one expert said.

Leggi questa versione → originale

morningstar.com4 g fa

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in…

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a…

Leggi questa versione → originale

npr.org4 g fa

A cancer vaccine made just for you. mRNA is back and it's fighting melanoma

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with Keytruda, an immunotherapy drug.

Leggi questa versione → originale

independent.co.uk4 g fa

Breakthrough melanoma vaccine would slash risk of the deadly cancer returning

An estimated 112,000 new melanoma cases and 8,500 deaths are expected this year

Leggi questa versione → originale

ansa.it4 g fa

Melanoma, a 5 anni vivo il 92% dei pazienti trattato con il vaccino personalizzato - Focus Tumore news -…

Vaccino mRNA personalizzato contro melanoma: 92,2% sopravvivenza a 5 anni vs 71,3%, riduce del 59% il rischio metastasi. Il modello di genomic personalization si replicherà su polmone e tumori ad alta mutazione, trasformando precision medicine in standard terapeutico.

Leggi questa versione → originale

Timeline cronologica

1. lunedì 1 giugno 2026·npr.org
   

   A cancer vaccine made just for you. mRNA is back and it's fighting melanoma

   A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with Keytruda, an immunotherapy drug.

2. lunedì 1 giugno 2026·nbcnews.com
   

   A personalized vaccine for melanoma cut the risk of cancer returning after five years

   If the vaccine is effective in a late-stage trial, it would be “paradigm-shifting,” one expert said.

3. lunedì 1 giugno 2026·morningstar.com
   

   Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage…

   At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction…

4. lunedì 1 giugno 2026·ansa.it
   

   Melanoma, a 5 anni vivo il 92% dei pazienti trattato con il vaccino personalizzato - Focus Tumore news - Ansa.it

   Dal congresso mondiale di oncologia ASCO in corso a Chicago arriva una importante conferma sull'efficacia del vaccino a mRna contro il melanoma, la cui sperimentazione è iniziata…

5. lunedì 1 giugno 2026·independent.co.uk
   

   Breakthrough melanoma vaccine would slash risk of the deadly cancer returning

   An estimated 112,000 new melanoma cases and 8,500 deaths are expected this year

6. martedì 2 giugno 2026·forbes.com
   

   New Study Shows How mRNA Vaccines Could Transform Cancer Treatment

   A doctor breaks down a new study on how mRNA vaccines in melanoma research could transform treatment and survival for cancer patients

7. martedì 2 giugno 2026·liberoquotidiano.it
   

   Melanoma, il vaccino ad hoc: crolla del 49% il rischio recidiva | Libero Quotidiano.it

   Un vaccino, combinato all'immunoterapia, ha dimostrato una clamorosa efficacia nell'evitare il rischio di una recidiva di un melanom...

8. martedì 2 giugno 2026·medpagetoday.com
   

   Melanoma Vaccine Halves Risk of Recurrence, Metastasis Over 5 Years

   Adjuvant approach will need confirmation from ongoing phase III trial, says expert